CVE:WMD - WeedMD Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
C$2.12 -0.04 (-1.85 %)
(As of 06/24/2018 07:04 AM ET)
Previous CloseC$2.12
Today's RangeC$2.10 - C$2.32
52-Week RangeC$0.68 - C$3.25
Volume2.07 million shs
Average Volume798,130 shs
Market CapitalizationC$190.81 million
P/E RatioN/A
Dividend YieldN/A
WeedMD Inc. produces and sells medical marijuana, including dried marijuana, cannabis oil, cannabis resin, marijuana plants, and marijuana seeds in Canada. The company is headquartered in Aylmer, Canada.

Receive WMD News and Ratings via Email

Sign-up to receive the latest news and ratings for WMD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic


Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A


EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-156.48%
Return on Equity-27.39%
Return on Assets-25.14%


Outstanding Shares101,282,000

The Truth About Cryptocurrencies

WeedMD (CVE:WMD) Frequently Asked Questions

What is WeedMD's stock symbol?

WeedMD trades on the Canadian Venture Exchange (CVE) under the ticker symbol "WMD."

When is WeedMD's next earnings date?

WeedMD is scheduled to release their next quarterly earnings announcement on Thursday, August, 30th 2018. View Earnings Estimates for WeedMD.

What price target have analysts set for WMD?

0 analysts have issued 12-month target prices for WeedMD's stock. Their forecasts range from C$3.50 to C$3.50. On average, they anticipate WeedMD's share price to reach C$3.50 in the next year. View Analyst Ratings for WeedMD.

Who are some of WeedMD's key competitors?

Who are WeedMD's key executives?

WeedMD's management team includes the folowing people:
  • Mr. Bruce Dawson-Scully, CEO & Director (Age 44)
  • Dr. Luc C. Duchesne Ph.D., Chief Scientific Officer (Age 57)
  • Mr. Keith Merker, CFO, Corp. Sec. & Director (Age 45)
  • Ms. Josephine DesLauriers, VP of HR

Has WeedMD been receiving favorable news coverage?

Media coverage about WMD stock has trended somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies positive and negative media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. WeedMD earned a coverage optimism score of 0.13 on Accern's scale. They also assigned headlines about the company an impact score of 44.16 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near future.

How do I buy shares of WeedMD?

Shares of WMD and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is WeedMD's stock price today?

One share of WMD stock can currently be purchased for approximately C$2.12.

How big of a company is WeedMD?

WeedMD has a market capitalization of C$190.81 million.

How can I contact WeedMD?

WeedMD's mailing address is 320 Bay St Suite 1600, TORONTO, ON M5H 4A6, Canada. The company can be reached via phone at +1-416-5153923.

MarketBeat Community Rating for WeedMD (WMD)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  26 (Vote Outperform)
Underperform Votes:  22 (Vote Underperform)
Total Votes:  48
MarketBeat's community ratings are surveys of what our community members think about WeedMD and other stocks. Vote "Outperform" if you believe WMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe WMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/24/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.